Salonpas Ad Claims Pass FTC Test After Firm Refuses NAD Review
This article was originally published in The Tan Sheet
Executive Summary
NAD cases do not go to FTC with a guarantee of enforcement, but firms should not ignore NAD requests for substantiation. FTC declined to enforce against Hisamitsu’s claims for Salonpas OTC pain relief patches after the firm declined to provide information for a NAD review prompted by a Pfizer challenge.